BridgeMD
New treatment option for Myeloid Malignancy
Official title An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies
ClinicalTrials.gov ID: NCT07619287
What this study is testing
What is BG-75202?
BG-75202 is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for myeloid malignancy.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of BG-75202 (KAT6A/B inhibitor) alone and in combination with other agents in patients with myeloid malignancies.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients must be ≥ 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place), inclusive, at the time of...
- Patients must have a confirmed diagnosis of myeloid malignancies based on 2016 World Health Organization criteria, and meet the following categories:
- Relapsed/refractory; myeloid malignancies after ≥1 prior systemic therapy, per ELN; 2022 criteria; patients with actionable genetic alteration must...
- Patients must have a stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.
You likely can't join if
- Prior exposure to KAT6A/B inhibitors/degraders.
- A diagnosis of acute promyelocytic leukemia or BCR-ABL-positive leukemia.
- Known central nervous system involvement by leukemia
- Use of antileukemic therapies without sufficient washout period Note: Other protocol defined Inclusion/Exclusion criteria may apply.
The study team makes the final eligibility decision.
Where it's taking place
- Kurralta Park, South Australia, Australia
- Nedlands, Western Australia, Australia
- Tianjin, Tianjin Municipality, China
- Auckland, New Zealand
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Kurralta Park, South Australia, Australia; Nedlands, Western Australia, Australia; Tianjin, Tianjin Municipality, China; Auckland, New Zealand. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.